Human immunodeficiency virus (HIV) is associated with motor and mood disorders, likely influenced by reactive microgliosis and subsequent neural damage. We have recapitulated aspects of this pathology in mice that conditionally express the neurotoxic HIV-1 regulatory protein, trans-activator of transcription (Tat). Progestogens may attenuate Tat-related behavioral impairments and reduce neurotoxicity in vitro, perhaps via progesterone's 5a-reductase-dependent metabolism to the neuroprotective steroid, allopregnanolone. To test this, ovariectomized female mice that conditionally expressed (or did not express) central HIV-1 Tat were administered vehicle or progesterone (4 mg/kg), with or without pretreatment of a 5a-reductase inhibitor (finasteride, 50 mg/kg). Tat induction significantly increased anxiety-like behavior in an open field, elevated plus maze and a marble burying task concomitant with elevated protein oxidation in striatum. Progesterone administration attenuated anxiety-like effects in the open field and elevated plus maze, but not in conjunction with finasteride pretreatment. Progesterone also attenuated Tat-promoted protein oxidation in striatum, independent of finasteride pretreatment. Concurrent experiments in vitro revealed Tat (50 nM)-mediated reductions in neuronal cell survival over 60 h, as well as increased neuronal and microglial intracellular calcium, as assessed via fura-2 AM fluorescence. Co-treatment with allopregnanolone (100 nM) attenuated neuronal death in time-lapse imaging and blocked the Tat-induced exacerbation of intracellular calcium in neurons and microglia. Lastly, neuronal-glial co-cultures were labeled for Iba-1 to reveal that Tat increased microglial numbers in vitro and co-treatment with allopregnanolone attenuated this effect. Together, these data support the notion that 5a-reduced pregnane steroids exert protection over the neurotoxic effects of HIV-1 Tat.
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Introduction
The advent of highly active antiretroviral therapies (HAART) has made it possible to reduce circulatory viral load of human immunodeficiency virus (HIV) to undetectable levels. However, HAART cannot eradicate HIV, in part due to cellular reservoirs that retain latent infection or low-levels of viral production residing within the central nervous system (CNS) where HAART penetration and/ or accumulation are reduced (Iglesias-Ussel and Romerio, 2011).
As such, neurotoxic HIV proteins continue to be produced within the CNS and are believed to underlie continuing progression of affective, cognitive, and motor dysfunction (a constellation of neurological symptoms referred to as ''neuroAIDS"; Hauser et al., 2007; Hong and Banks, 2015; Nath, 2015) .
Within the CNS parenchyma, microglia act as macrophages and are thought to be the primary resident cell type to harbor the virus (Gendelman and Meltzer, 1989; Meltzer and Gendelman, 1992) . Given that HIV does not infect neurons, microglial activation and the production of excitotoxic and inflammatory factors likely contribute to the neurodegenerative and behavioral profile observed in neuroAIDS. One viral protein produced by infected microglia (and infected astrocytes to a lesser degree) that may particularly contribute to these effects is the HIV-1 trans-activator of transcription (Tat).
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